Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company FAB Pharma S.A.S.
DescriptionIntravenous narrow-spectrum antibiotic that inhibits the fatty acid biosynthesis I (FAB I) enzyme
Molecular Target Fatty acid biosynthesis 1 (FAB1)
Mechanism of ActionCell membrane integrity disruption
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationStaphylococcus
Indication DetailsTreat methicillin-resistant Staphylococcus aureus (MRSA) infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today